Display options
Cite
Zapatero-Belinchón FJ, Moeller R, Lasswitz L, et al. Fluvastatin mitigates SARS-CoV-2 infection in human lung cells. iScience. 2021;24(12):103469doi: 10.1016/j.isci.2021.103469.
Zapatero-Belinchón, F. J., Moeller, R., Lasswitz, L., van Ham, M., Becker, M., Brogden, G., Rosendal, E., Bi, W., Carriquí-Madroñal, B., Islam, K., Lenman, A., Gunesch, A. P., Kirui, J., Pietschmann, T., Överby, A. K., Jänsch, L., & Gerold, G. (2021). Fluvastatin mitigates SARS-CoV-2 infection in human lung cells. iScience, 24(12), 103469. https://doi.org/10.1016/j.isci.2021.103469
Zapatero-Belinchón, Francisco J, et al. "Fluvastatin mitigates SARS-CoV-2 infection in human lung cells." iScience vol. 24,12 (2021): 103469. doi: https://doi.org/10.1016/j.isci.2021.103469
Zapatero-Belinchón FJ, Moeller R, Lasswitz L, van Ham M, Becker M, Brogden G, Rosendal E, Bi W, Carriquí-Madroñal B, Islam K, Lenman A, Gunesch AP, Kirui J, Pietschmann T, Överby AK, Jänsch L, Gerold G. Fluvastatin mitigates SARS-CoV-2 infection in human lung cells. iScience. 2021 Dec 17;24(12):103469. doi: 10.1016/j.isci.2021.103469. Epub 2021 Nov 18. PMID: 34812415; PMCID: PMC8599137.
Copy Download .nbib Format: NLM
Share it on

iScience. 2021 Dec 17;24(12):103469. doi: 10.1016/j.isci.2021.103469. Epub 2021 Nov 18.

Fluvastatin mitigates SARS-CoV-2 infection in human lung cells.

iScience

Francisco J Zapatero-Belinchón, Rebecca Moeller, Lisa Lasswitz, Marco van Ham, Miriam Becker, Graham Brogden, Ebba Rosendal, Wenjie Bi, Belén Carriquí-Madroñal, Koushikul Islam, Annasara Lenman, Antonia P Gunesch, Jared Kirui, Thomas Pietschmann, Anna K Överby, Lothar Jänsch, Gisa Gerold

Affiliations

  1. Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, A Joint Venture Between the Medical School Hannover and the Helmholtz Centre for Infection Research, 30625 Hannover, Germany.
  2. Department of Clinical Microbiology, Virology, Umeå University, 90185 Umeå, Sweden.
  3. Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, 90185 Umeå, Sweden.
  4. Department of Biochemistry & Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, 30559 Hannover, Germany.
  5. Cellular Proteome Research Group, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany.
  6. The Laboratory for Molecular Infection Medicine Sweden (MIMS), R893+F4 Umeå, Sweden.
  7. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
  8. German Centre for Infection Research (DZIF), Partner site Hannover-Braunschweig, 30625 Hannover, Germany.

PMID: 34812415 PMCID: PMC8599137 DOI: 10.1016/j.isci.2021.103469

Abstract

Clinical data of patients suffering from COVID-19 indicates that statin therapy, used to treat hypercholesterolemia, is associated with a better disease outcome. Whether statins directly affect virus replication or influence the clinical outcome through modulation of immune responses is unknown. We therefore investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that only fluvastatin inhibited low and high pathogenic coronaviruses

© 2021 The Author(s).

Keywords: Drugs; Virology

Conflict of interest statement

The authors declare no competing interests.

References

  1. Hypertension. 2001 Jun;37(6):1450-7 - PubMed
  2. Euro Surveill. 2020 Jan;25(3): - PubMed
  3. Nucleic Acids Res. 2007;35(17):5975-84 - PubMed
  4. Nat Methods. 2012 Jun 28;9(7):676-82 - PubMed
  5. Eur Heart J Cardiovasc Pharmacother. 2020 Nov 02;: - PubMed
  6. Cell Metab. 2020 Aug 4;32(2):176-187.e4 - PubMed
  7. Lancet Respir Med. 2020 Jul;8(7):687-695 - PubMed
  8. Biochem J. 2006 Jun 1;396(2):219-26 - PubMed
  9. N Engl J Med. 2020 Jun 25;382(26):2534-2543 - PubMed
  10. Cell Host Microbe. 2010 Nov 18;8(5):445-54 - PubMed
  11. Annu Rev Pharmacol Toxicol. 2005;45:89-118 - PubMed
  12. J Exp Med. 2004 Aug 16;200(4):541-7 - PubMed
  13. Circulation. 1998 Mar 31;97(12):1129-35 - PubMed
  14. Cell. 2021 Jan 7;184(1):106-119.e14 - PubMed
  15. Sci Adv. 2021 Feb 5;7(6): - PubMed
  16. Cell Res. 2020 Mar;30(3):269-271 - PubMed
  17. Br J Clin Pharmacol. 2012 Apr;73(4):518-35 - PubMed
  18. Metabolism. 2020 Dec;113:154375 - PubMed
  19. Virology. 2008 May 25;375(1):59-72 - PubMed
  20. J Cardiovasc Pharmacol Ther. 2001 Apr;6(2):137-45 - PubMed
  21. Am J Respir Crit Care Med. 2019 Nov 15;200(10):1282-1293 - PubMed
  22. Cell Rep. 2021 Apr 6;35(1):108940 - PubMed
  23. Metabolism. 1992 Mar;41(3):229-35 - PubMed
  24. J Clin Lipidol. 2021 Jan-Feb;15(1):68-78 - PubMed
  25. Virology. 2009 Jun 20;389(1-2):8-19 - PubMed
  26. Elife. 2019 Jan 11;8: - PubMed
  27. Prog Cardiovasc Dis. 2021 Jul-Aug;67:53-64 - PubMed
  28. Arch Virol. 2016 Feb;161(2):327-33 - PubMed
  29. Arch Med Sci. 2020 Apr 25;16(3):490-496 - PubMed
  30. Clin Microbiol Infect. 2019 Mar;25(3):280-289 - PubMed
  31. Heart Vessels. 2017 May;32(5):618-627 - PubMed
  32. PLoS One. 2010 Nov 15;5(11):e13984 - PubMed
  33. Arterioscler Thromb Vasc Biol. 1997 Feb;17(2):265-72 - PubMed
  34. Antiviral Res. 2021 Jun;190:105064 - PubMed
  35. Cardiovasc Ther. 2015 Dec;33(6):338-46 - PubMed
  36. Nature. 2020 May;581(7809):465-469 - PubMed
  37. Bioinformatics. 2014 Feb 15;30(4):523-30 - PubMed
  38. J Biol Chem. 2021 Jul;297(1):100821 - PubMed
  39. Antiviral Res. 2013 Sep;99(3):417-35 - PubMed
  40. Cell. 2021 Jan 7;184(1):92-105.e16 - PubMed
  41. FASEB J. 2019 Aug;33(8):9516-9525 - PubMed
  42. Am J Physiol Lung Cell Mol Physiol. 2002 Feb;282(2):L226-36 - PubMed
  43. Circulation. 2001 Feb 20;103(7):926-33 - PubMed
  44. JAMA. 2013 Oct 23;310(16):1692-700 - PubMed
  45. Nature. 2021 Jun;594(7862):246-252 - PubMed
  46. Sci Rep. 2019 Nov 26;9(1):17603 - PubMed
  47. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15865-70 - PubMed
  48. Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450 - PubMed
  49. Virol J. 2005 Aug 22;2:69 - PubMed
  50. NCHS Data Brief. 2014 Dec;(177):1-8 - PubMed
  51. Circ Res. 2017 Jan 6;120(1):229-243 - PubMed
  52. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934 - PubMed
  53. J Clin Med. 2020 Jun 18;9(6): - PubMed
  54. Nat Protoc. 2016 Dec;11(12):2301-2319 - PubMed
  55. Int J Mol Sci. 2020 Jul 06;21(13): - PubMed
  56. J Virol. 2015 Aug;89(16):8318-33 - PubMed
  57. Am J Respir Crit Care Med. 2017 Nov 15;196(10):1325-1336 - PubMed
  58. Eur Respir J. 2013 May;41(5):1147-56 - PubMed
  59. Methods Enzymol. 2019;626:587-620 - PubMed
  60. PLoS Biol. 2021 Mar 17;19(3):e3001143 - PubMed
  61. Atherosclerosis. 2014 Jan;232(1):141-8 - PubMed
  62. Br J Clin Pharmacol. 2011 Jul;72(1):164-5 - PubMed
  63. PLoS Pathog. 2016 Jan 06;12(1):e1005357 - PubMed
  64. Sci Rep. 2020 Oct 15;10(1):17458 - PubMed
  65. J Geriatr Cardiol. 2013 Jun;10(2):151-8 - PubMed
  66. Biochem Biophys Res Commun. 2008 May 2;369(2):344-9 - PubMed
  67. Virology. 2008 Nov 25;381(2):215-21 - PubMed
  68. Microbes Infect. 2007 Jan;9(1):96-102 - PubMed
  69. Cell. 2020 May 28;181(5):1036-1045.e9 - PubMed
  70. Nature. 2020 Sep;585(7826):588-590 - PubMed
  71. J Cell Mol Med. 2001 Oct-Dec;5(4):378-87 - PubMed
  72. Nat Med. 2020 Aug;26(8):1205-1211 - PubMed
  73. mBio. 2018 May 1;9(3): - PubMed
  74. Science. 2017 Dec 1;358(6367): - PubMed
  75. Cell. 2020 Apr 16;181(2):271-280.e8 - PubMed
  76. Nature. 2020 Jul;583(7816):469-472 - PubMed
  77. Signal Transduct Target Ther. 2021 May 8;6(1):180 - PubMed
  78. Nature. 2020 Jul;583(7816):459-468 - PubMed
  79. Nat Microbiol. 2021 Mar;6(3):339-353 - PubMed
  80. FEBS J. 2016 Jan;283(1):88-101 - PubMed
  81. Pharmacol Ther. 1999 Dec;84(3):413-28 - PubMed
  82. Nat Commun. 2021 Feb 26;12(1):1325 - PubMed
  83. Nat Med. 2013 Jun;19(6):722-9 - PubMed

Publication Types